Vertex Pharmaceuticals on Wednesday selected two cystic fibrosis drugs to advance into late-stage clinical trials as part of different triple-combination regimens. The decision was based on new clinical data, also disclosed Wednesday, showing large improvements in lung function for patients with a type of cystic fibrosis that is genetically resistant to all treatments now on the market.

If the two new drugs reach the market, Vertex would be able to successfully treat the underlying cause of cystic fibrosis in roughly 90 percent of the 75,000 patients worldwide, up from roughly half.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy